With aging populations and more sophisticated markets growing in the Asia Pacific region, multinational corporations including Medtronic plc and Olympus Corp. are tapping digitalization, robotics and innovation platforms to seek med-tech solutions.
Endogena Therapeutics Inc., of San Francisco, has raised another $20 million in a series A funding round to progress a regenerative medicine that could use stem cells to “heal” the damage caused by eye disease retinitis pigmentosa (RP).
New hires and promotions in the med-tech industry, including: Abbott, Cutera, Establishment Labs Holdings, Hyperfine, Inogen, Neogenomics, Nurosene, Turner Imaging.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Galderma, Intervene, Urotronic.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Baxter, Clearsky, Deep Knowledge Group, Henry Schein, Hillrom, Hospital IQ, Medtronic, Masimo, Omnia, Opsens, Quant Biomarkers, Siemens Healthineers, Shanghai Accurature.
Venus Medtech (Hangzhou) Inc. reported it has acquired 100% equity interest and corresponding equity in Cardiovalve Ltd. for $300 million. Or Yehuda, Israel-based Cardiovalve produces the Cardiovalve system, a transcatheter interventional replacement product for mitral or tricuspid regurgitation.
Stereotaxis Corp. reported positive results showing its robotic magnetic navigation (RMN) system significantly reduces the incidence of silent cerebral embolism (SCE) in patients undergoing atrial fibrillation (AF) ablation vs. hand-held catheters. The prospective, multicenter study is believed to be the first to compare AF ablation using RMN with manual control and to highlight the benefit in lowering SCE risk.
RSS
